• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,208.12 +80.43 (+7.13%)
    Official Closing Price Updated: 4:10 PM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? ↗
    Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead. 
    Via The Motley Fool
    Discover which S&P500 stocks are making waves on Friday. ↗
    Via Chartmill
    News headline image
    Why Is Eli Lilly (LLY) Stock Soaring Today
    What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's commit... 
    Via StockStory
    News headline image
    Snap’s Specs Gamble ↗
    The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish. 
    Via The Motley Fool
    Topics Workforce
    Eli Lilly & Co (NYSE:LLY) Screens as a Top Growth Stock with a Strong Technical Breakout Setup ↗
    Via Chartmill
    Eli Lilly & Co. (NYSE:LLY): A High-Growth Champion Aligned with Navellier's Proven Strategy ↗
    Via Chartmill
    Friday's session: top gainers and losers in the S&P500 index ↗
    Via Chartmill
    News headline image
    Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value? ↗
    Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗
    These aren't for the faint of heart. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗
    Novo Nordisk is no longer the front-runner, but it's not out of the running, either. 
    Via The Motley Fool
    News headline image
    Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success ↗
    ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase. 
    Via Benzinga
    News headline image
    Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’ ↗
    Nancy Pelosi Stock Tracker told investors to "keep an eye" on Eli Lilly and Nokia after Trump praised the companies in Pennsylvania. 
    Via Benzinga
    Topics Government
    News headline image
    The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch ↗
    These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Why Illumina (ILMN) Stock Is Trading Up Today
    What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to ... 
    Via StockStory
    News headline image
    Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact ↗
    Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally. 
    Via Benzinga
    News headline image
    White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President' ↗
    White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide through an FDA program. 
    Via Benzinga
    Topics Government
    News headline image
    The Vanguard ETF That Could Set You Up for Life if You Buy It Today ↗
    Consistency can do a lot of the heavy lifting for you. 
    Via The Motley Fool
    Topics ETFs Economy
    News headline image
    1 Mid-Cap Stock to Own for Decades and 2 We Question
    Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
    Via StockStory
    Topics Retirement
    News headline image
    Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle ↗
    Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets. 
    Via Benzinga
    Topics Bankruptcy
    News headline image
    Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy? ↗
    The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns. 
    Via The Motley Fool
    News headline image
    3 Monster Stocks to Hold for the Next 10 Years ↗
    These healthcare stocks may be the building blocks of a winning portfolio. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    2 Underrated Weight Loss Stocks to Buy and Hold ↗
    They look well-positioned to grab a slice of the fast-growing anti-obesity market. 
    Via The Motley Fool
    News headline image
    Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
    As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗
    Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed. 
    Via The Motley Fool
    News headline image
    WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
    Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend... 
    Via Newsfile
    News headline image
    1 Vanguard Index Fund Could Turn $450 Per Month Into a $905,200 Portfolio That Pays $16,400 in Annual Dividend Income ↗
    Young adults with median earnings can build sizable portfolios that pay a hefty amount of passive income by retirement. 
    Via The Motley Fool
    Topics ETFs Retirement
    News headline image
    13 Stocks Are Members of the $1 Trillion Club. Here's the Best Pick to Buy Right Now. ↗
    Want to really go big? One megacap stock offers an especially attractive risk-reward proposition. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors? ↗
    Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? ↗
    Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen. 
    Via The Motley Fool
    News headline image
    Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant? ↗
    Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.